1. CAR T Cell Therapy for Neuroblastoma
   Rebecca M. Richards et al, 2018, Frontiers in Immunology CrossRef
2. CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
   Pauline Thomas et al, 2021, Cancers CrossRef
3. Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse model
   Kosuke Kambe et al, 2022, Pediatric Surgery International CrossRef
4. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
   Iris Lodewijk et al, 2023, Frontiers in Immunology CrossRef
5. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
   Ramona Erber et al, 2021, Cancers CrossRef
6. Target selection and clinical chimeric antigen receptor T cell activity against solid tumors
   Eric von Hofe et al, 2023, iLABMED CrossRef
7. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
   Stefano Mastrangelo et al, 2021, International Journal of Molecular Sciences CrossRef
8. The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma
   Enrico Rango et al, 2022, Biomedicines CrossRef
9. In Vivo Cytoreduction Studies and Cell Sorting–Enhanced Tumor-Cell Detection in High-Risk Neuroblastoma Patients: Implications for Leukapheresis Strategies
   Lawrence B. Faulkner et al, 2000, Journal of Clinical Oncology CrossRef
10. Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
    Fabio Morandi et al, 2021, Vaccines CrossRef
11. GD2-targeting therapy: a comparative analysis of approaches and promising directions
    Julia Philippova et al, 2024, Frontiers in Immunology CrossRef
12. Monoclonal Antibody Therapies for High Risk Neuroblastoma
    Wayne L Furman, 2021, Biologics: Targets and Therapy CrossRef
13. A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group
    Kaci L. Osenga et al, 2006, Clinical Cancer Research CrossRef
14. Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
    John Inge Johnsen et al, 2019, Frontiers in Molecular Neuroscience CrossRef
15. Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)
    A.-M. Arendt et al, 2023, Cancer Immunology, Immunotherapy CrossRef
16. Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
    Suresh Madheswaran et al, 2020, Anti-Cancer Agents in Medicinal Chemistry CrossRef
17. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
    Giuseppe Barone et al, 2021, Pediatric Drugs CrossRef
18. Biology of GD2 ganglioside: implications for cancer immunotherapy
    Pierre Machy et al, 2023, Frontiers in Pharmacology CrossRef
19. Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma
    T. V. Shamanskaya et al, 2020, Pediatric Hematology/Oncology and Immunopathology CrossRef
20. Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors
    Veronica Bensa et al, 2021, Pharmaceuticals CrossRef